Induction chemotherapy with docetaxel, cisplatin, 5 FU, followed by radiotherapy plus cisplatin or cetuximab, in organ preservation in piriform sinus carcinomas.

被引：0
|
作者：
Fayette, Jerome
Fuchsmann, Carine
Tartas, Sophie
Favrel, Veronique
Pommier, Pascal
Zrounba, Philippe
Ramade, Antoine
Racadot, Severine
Ceruse, Philippe
Poupart, Marc
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Univ Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[3] CRLCC Leon Berard, Lyon, France
[4] Univ Lyon, Hosp E Herriot, Lyon, France
[5] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[6] Univ Lyon, Opital Croix Rousse, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A RETROSPECTIVE, MULTICENTER STUDY OF THE TOLERANCE OF INDUCTION CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOLLOWED BY RADIOTHERAPY WITH CONCOMITANT CETUXIMAB IN 46 CASES OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Buiret, Guillaume
    Combe, Claire
    Favrel, Veronique
    Pommier, Pascal
    Martin, Laurent
    Ecochard, Rene
    Fayette, Jerome
    Tartas, Sophie
    Ramade, Antoine
    Ceruse, Philippe
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (02): : 430 - 437
  • [42] Re: Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
    Haddad, Robert I.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (16) : 1157 - U68
  • [43] Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer
    Bossi, P.
    Orlandi, E.
    Bergamini, C.
    Locati, L. D.
    Granata, R.
    Mirabile, A.
    Parolini, D.
    Franceschini, M.
    Fallai, C.
    Olmi, P.
    Quattrone, P.
    Potepan, P.
    Gloghini, A.
    Miceli, R.
    Mattana, F.
    Scaramellini, G.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2495 - 2500
  • [44] Feasibility of induction docetaxel, cisplatin, 5-fluorouracil cetuximab (TPF-C) followed by concurrent cetuximab radiotherapy for locally advanced head and neck squamous cell carcinoma
    Charalambakis, Nikolaos
    Kouloulias, Vassilis
    Vaja, Helena
    Pectasides, Dimitrios
    Rampias, Theodoros
    Economopoulos, Theofanis
    Katsaounis, Panagiotis
    Siolos, Spiros
    Bartzi, Valentina
    Perisanidis, Christos
    Laschos, Konstantinos
    Maragoudakis, Pavlos
    Proikas, Konstantinos
    Papadimitriou, Nikolaos
    Papadogeorgakis, Nikolaos
    Georgopoulou, Helen
    Zygogianni, Anna
    Artopoulou, Ioli
    Pappa, Eleni
    Dimitriadis, George
    Psyrri, Amanda
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [45] Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck carcinomas.
    Allal, AS
    Zwahlen, D
    Becker, M
    Dulguerov, P
    Mach, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 518S - 518S
  • [46] Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC).
    Hitt, Ricardo
    Mesia, Ricard
    Grau, Juan Jose
    Iglesias, Lara
    Del Barco, Elvira
    Lozano, Alicia
    Trufero, Javier Martinez
    Giron, Carlos Garcia
    Martin, Ana Lopez
    Hernandez, Juan Jesus Cruz
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Locoregionally advanced nasopharyngeal carcinoma:: Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin -: A phase II study
    Ferrari, D.
    Chiesa, F.
    Codeca, C.
    Calabrese, L.
    Jereczek-Fossa, B. A.
    Alterio, D.
    Fiore, J.
    Luciani, A.
    Floriani, I.
    Orecchia, R.
    Foa, P.
    ONCOLOGY, 2008, 74 (3-4) : 158 - 166
  • [48] Study of induction docetaxel, cisplatin, cetuximab and bevacizumab (TPE-A) followed by concurrent radiotherapy, cisplatin, cetuximab and bevacizumab (XPE-A) in patients with high-risk locally advanced head and neck cancer
    Akinyi-Joseph, Grace M.
    Wehbe, Ahmad Mouhamad
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Induction Chemotherapy with Cisplatin and Gemcitabine followed by Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma
    Ou, D.
    He, X.
    Hu, C.
    Zhu, G.
    Ying, H.
    Wu, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S404 - S405
  • [50] Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
    Kitadani, Junya
    Ojima, Toshiyasu
    Hayata, Keiji
    Goda, Taro
    Takeuchi, Akihiro
    Tominaga, Shinta
    Fukuda, Naoki
    Nakai, Tomoki
    Yamaue, Hiroki
    Kawai, Manabu
    ONCOLOGY, 2024, 102 (03) : 228 - 238
12345